Status and phase
Conditions
Treatments
About
To determine and compare the safety and tolerability of 3 doses of LXR015-1 in HIV-infected patients.
Full description
Patients will be randomized to 1 of 3 doses of oral LXR015-1 for 28 days and patients will be monitored for adverse events for the duration of the study. Patients will continue to be monitored for least 4 weeks after completion of the dosing.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Patients must have:
Prior Medication:
Allowed:
Acute therapy for opportunistic infections or serious AIDS defining infections must be completed at least 28 days before study entry.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
NOTE:
Concurrent Treatment:
Excluded:
Radiation therapy.
Patients with the following prior condition are excluded:
A known history of hypersensitivity reaction to soy protein or soy lecithin. NOTE:
Excluded:
Required:
Patient must be taking a stable regimen (about 8 weeks) of anti-viral, anti-opportunistic infection and/or anti-diarrheal (if patient has diarrhea) medications.
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal